With an estimated 9.3 percent of the world’s adult population living with diabetes, experts are making remarkable accomplishments to manage diabetes efficiently.
DreaMed Diabetes AI LTD. — a company that offers AI solutions for diabetes — has received U.S Food and Drug Administration (FDA) clearance for its diabetes decision-support tool, Advisor Pro.
Advisor Pro is the first ever decision support system to get FDA clearance on using data by patients who use insulin pumps and monitor their blood glucose levels using Continuous Glucose Monitoring (CGM) or Self Monitor the Blood Glucose (SMBG). The system was already in action for patients with diabetes type 1, but the new clearance allows to expand Advisor Pro’s target population to patients with type 2 diabetes.
Advisor Pro uses a combination of clinical science and artificial intelligence to assist medical professionals in managing their patients with diabetes who use insulin pumps and keep track of their glucose levels using CGM or SMBG. It lets health professionals offer personalized, real-time recommendations to patients who have diabetes. Frequent titration of insulin through remote care makes diabetes management easier and more effective.
Advisor Pro follows four steps:
- Patients upload data from CGM, SMBG, or insulin pump to the data management system.
- Advisor Pro pulls this data and analyzes it through MD Logic Algorithm for highs, lows, and any specific patterns.
- It then produces a full titration recommendation including basal rate optimization, correction factor, carb ratio, and personalized tips.
- The health care provider reviews the recommendation, edit, and share with patients via an app, email, or print.
Considering that the US has one endocrinologist for every 41,000 adults, Advisor Pro is a great addition to managing diabetes efficiently. Wider use of this technology could put us another step closer to preventing unnecessary hospitalizations to deal with complications of diabetes.